利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.036 秒)

    Tissue factor pathway inhibitor-3
    22.
    发明授权
    Tissue factor pathway inhibitor-3 失效
    组织因子途径抑制剂-3

    公开(公告)号：US06262233B1

    公开(公告)日：2001-07-17

    申请号：US09013896

    申请日：1998-01-27

    申请人： Reiner L. Gentz ,  Tsu-An Hsu ,  Craig A. Rosen ,  Jian Ni

    发明人： Reiner L. Gentz ,  Tsu-An Hsu ,  Craig A. Rosen ,  Jian Ni

    IPC分类号： C07K400

    CPC分类号： C07K14/8114 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention relates to a novel TFPI-3 protein which is a member of the tissue factor protease inhibitor family. In particular, isolated nucleic acid molecules are provided encoding human TFPI-3 proteins. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.

    摘要翻译： 本发明涉及作为组织因子蛋白酶抑制剂家族成员的新型TFPI-3蛋白。 特别地，提供编码人TFPI-3蛋白质的分离的核酸分子。 还提供TFPI-3多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定TFPI-3活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测止血系统相关疾病的诊断方法和治疗止血系统相关疾病的治疗方法。

    Treatment of coronavirus infection
    24.
    发明授权
    Treatment of coronavirus infection 失效
    冠状病毒感染的治疗

    公开(公告)号：US07544712B1

    公开(公告)日：2009-06-09

    申请号：US10856281

    申请日：2004-05-28

    申请人： Tsu-An Hsu ,  Hsing-Pang Hsieh ,  Yu-Sheng Chao ,  Chi-Min Chen ,  Jia-Tsrong Jan ,  Hwan-Wun Liu

    发明人： Tsu-An Hsu ,  Hsing-Pang Hsieh ,  Yu-Sheng Chao ,  Chi-Min Chen ,  Jia-Tsrong Jan ,  Hwan-Wun Liu

    IPC分类号： A61K31/33 ,  A01N47/10

    CPC分类号： A61K31/33

    摘要： A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine, thioridazine, chlorprothixene, thiothixene, clozapine, haloperidol, haloperidol decanoate, loxapine, molindone, olanzapine, pimozide, quetiapine, risperidone, and amitriptyline.

    摘要翻译： 一种通过向需要治疗的受试者施用有效量的一种或多种以下化合物来治疗冠状病毒感染的方法：阿伐黄素，血根碱，胺碘酮，氯丙嗪，克罗米酚，二氢麦角胺，双嘧达莫，埃米汀，麻黄素，丙氯拉嗪， 丙诺霉素，氨基吖啶，氟奋乃静，非诺替尔，紫苏碱，恩替洛尔，阿替洛尔，奈非泮，奈非泮，放线菌酮，阿维菌素B1，苯普利，桂酸，乙胺，对羟基苯胺，甲基苄索铵，氯硝柳胺，pipobroman，homidium，calcimycin，茴香霉素，metergoline，amodiaquine，达那唑， 依托泊汀，间苯二酚，替康罗林，美勃司宁，间苯丙胺，三氟丙嗪，氯替噻吩，环苯扎林，依诺沙星，磺胺三苯胺，莫能菌素，尼日利亚，奋乃静，甲氧胺，阿司咪唑，三氟拉嗪，吖啶鎓，鱼藤酮， ，环孢菌素，哌甲酯，霉酚酸， 乙氮嗪，美索达嗪，硫利达嗪，氯普ix辛，硫代四氢噻吩，氯氮平，氟哌啶醇，氟哌啶醇癸酸酯，洛沙平，莫洛多内，奥氮平，匹莫齐特，喹硫平，利培酮和阿米替林。